Back to catalog

Haematology · Oncology

IMPEDE-VTE Score calculator

Enter the published formula inputs below to calculate and interpret this score.

Clinical inputs

Dexamethasone
Existing thromboprophylaxis or anticoagulation

Result

Anyone can run this calculator. Sign in to save, favourite, or send the result.

0

Score ≤3 — lowest-risk group

Band: Score ≤3 — lowest-risk group

Interpretation. Score ≤3 — lowest-risk group

Suggested management. Derivation cohort: 6-month cumulative VTE incidence 3.3% (95% CI 2.6–4.1%).

IMPEDE-VTE Score: 0 — Score ≤3 — lowest-risk group. Interpretation: Score ≤3 — lowest-risk group What to do: Derivation cohort: 6-month cumulative VTE incidence 3.3% (95% CI 2.6–4.1%). Inputs: Immunomodulatory drug (thalidomide, lenalidomide, pomalidomide) (+4): false; BMI ≥25 kg/m² (+1): false; Pelvic, hip or femur fracture (from 30 days before diagnosis to start of therapy) (+4): false; Erythropoiesis-stimulating agent (+1): false; Dexamethasone: none; Doxorubicin (+3): false; Asian or Pacific Islander (−3): false; Tunneled line or central venous catheter (+2): false; Existing thromboprophylaxis or anticoagulation: none; History of venous thromboembolism (+5): false Source: Sanfilippo KM et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 2019;94(11):1176-1184. DOI: 10.1002/ajh.25603. PMID: 31379000. Table 3: immunomodulatory drug +4; BMI >=25 kg/m2 +1; pelvic, hip or femur fracture (30 days before diagnosis to start of therapy) +4; erythropoiesis-stimulating agent +1; dexamethasone high dose (>160 mg/month) +4 or low dose +2; doxorubicin +3; Asian/Pacific Islander -3; prior VTE +5; tunneled line/central venous catheter +2; therapeutic LMWH or warfarin -4 or prophylactic LMWH or aspirin -3. Table 4 derivation 6-month cumulative VTE incidence: score <=3 3.3%; 4-7 8.3%; >=8 15.2%. (2019)

Ruqelo is AI and can make mistakes. Check important information.

Clinical inputs

  • Immunomodulatory drug (thalidomide, lenalidomide, pomalidomide) (+4)
  • BMI ≥25 kg/m² (+1)
  • Pelvic, hip or femur fracture (from 30 days before diagnosis to start of therapy) (+4)
  • Erythropoiesis-stimulating agent (+1)
  • Dexamethasone
  • Doxorubicin (+3)
  • Asian or Pacific Islander (−3)
  • Tunneled line or central venous catheter (+2)
  • Existing thromboprophylaxis or anticoagulation
  • History of venous thromboembolism (+5)

Primary source

Sanfilippo KM et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 2019;94(11):1176-1184. DOI: 10.1002/ajh.25603. PMID: 31379000. Table 3: immunomodulatory drug +4; BMI >=25 kg/m2 +1; pelvic, hip or femur fracture (30 days before diagnosis to start of therapy) +4; erythropoiesis-stimulating agent +1; dexamethasone high dose (>160 mg/month) +4 or low dose +2; doxorubicin +3; Asian/Pacific Islander -3; prior VTE +5; tunneled line/central venous catheter +2; therapeutic LMWH or warfarin -4 or prophylactic LMWH or aspirin -3. Table 4 derivation 6-month cumulative VTE incidence: score <=3 3.3%; 4-7 8.3%; >=8 15.2%. (2019)

View source